Peptides and Ageing — Telomerase Activation by Epitalon

Human fetal fibroblasts (HFF) and peripheral blood lymphocytes were cultured and treated with Epitalon at concentrations of 10⁻⁵ to 10⁻¹¹ M. Telomerase activity was measured by the TRAP (Telomere Repeat Amplification Protocol) assay. Telomere length was assessed by Southern blotting of terminal restriction fragments (TRF). Control cells received vehicle only. p53 status was assessed to determine whether the activation pathway was p53-dependent.

Epitalon induced telomerase activity in human fetal fibroblasts at all tested concentrations, with peak activity at 10⁻⁷ M. Telomere length increased in treated cells relative to controls after the treatment period. Critically, the telomerase activation occurred in normal somatic cells (not cancer cells) via a p53-independent pathway — distinguishing it from oncogenic telomerase activation mechanisms. Lymphocytes treated with Epitalon showed similar telomerase induction, suggesting the effect is not cell-type specific within somatic tissues.

The study used fetal rather than adult or aged cells, which may not fully reflect telomere biology in aging tissues. Sample sizes were relatively small. The long-term consequences of Epitalon-induced telomerase activation in normal somatic cells have not been fully characterised. Replication of these findings by independent groups is limited.

This paper establishes Epitalon''s primary mechanism of action — telomerase activation in normal somatic cells — and is the foundational reference for all Epitalon longevity research. The p53-independent mechanism is particularly significant because it suggests telomerase activation without the oncogenic risk associated with p53-pathway telomerase inducers.